Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Immune Checkpoint Inhibitors (ICIs) and Tyrosine Kinase Inhibitors (TKIs) Therapy for Hepatocellular Carcinoma (HCC)：a Multicenter, Retrospective Study on the Real-world in China

NCT05420922 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05420922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Immune Checkpoint Inhibitors (ICIs) and Tyrosine Kinase Inhibitors (TKIs) Therapy for Hepatocellular Carcinoma (HCC)：a Multicenter, Retrospective Study on the Real-world in China
Lead sponsor
Tongji Hospital
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2021
Completion date
December 31, 2022
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effects of immunotherapy, hepatocellular carcinoma, programmed cell death 1